• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Blogs » The Carlat Psychiatry Podcast » Two Updates on Pimavenserin [60 Sec Psych]

The Carlat Psychiatry Podcast
The Carlat Psychiatry Podcast RSS FeedRSS

Clear, engaging, and practical updates on clinical psychiatry.
Earn CME for listening to the podcast with a Podcast CME Subscription.
Listen for free here or using Apple Podcasts, Android, or Stitcher.

Two Updates on Pimavenserin [60 Sec Psych]

October 21, 2020

Last April we reported on Pimavenserin – Nuplazid – the novel antipsychotic that’s FDA approved in psychosis related to parkinson’s disease. In that article we mentioned a randomized controlled trial from Mass General – the CLARITY trial - that showed promising augmentation effects when Pimavenserin was added to an antidepressant in major depressive disorder. Now comes a secondary analysis of that study, which found a significant reduction in anxiety symptoms as well. [Link and Link]


Published On: 10/21/2020


Duration: 3 minutes, 9 seconds


Transcript:


Last April we reported on Pimavenserin – Nuplazid – the novel antipsychotic that’s FDA approved in psychosis related to parkinson’s disease. In that article we mentioned a randomized controlled trial from Mass General – the CLARITY trial - that showed promising augmentation effects when Pimavenserin was added to an antidepressant in major depressive disorder. Now comes a secondary analysis of that study, which found a significant reduction in anxiety symptoms as well. 

This was a large, 5 week, randomized placebo controlled trial of 151 patients with treatment resistant depression who had failed two trials of antidepressants. The original study showed significant improvement on the Hamilton depression scale when  Pimavenserin was added to the antidepressant. This secondary analysis looked at the anxiety/somatization factor of the scale and also saw improvement – with moderate effect size of 0.6. The dose of pimavanserin was 34 mg a day.

The results are encouraging, but need replication, and in the case of anxiety they are only post-hoc results.

Separately, Pimavenserin is pursuing FDA approval in psychosis related to dementia. The company submitted their application to the FDA after their phase 3 HARMONY trial showed that Pimavenserin might reduce the risk of relapse into psychosis in patients with dementia due to various causes – alzheimers, Lewy Body, Parkinson’s, Vascular, and frontal-temporal dementia. That’s encouraging, as those of you who are studying for your board exams will probably recall that antipsychotics are relatively contraindicated in Lewy Body dementia.

Earlier, a phase II study had shown reduction in psychosis in dementia with Pimavenserin compared to placebo after 6 weeks. The new study is a discontinuation study. 351 patients with dementia related psychosis were randomized to stay on or discontinue Pimavenserin after 12 weeks on the drug. The risk of relapse into psychosis was 3 times higher in the ones who came off Pimavenserin.

Got feedback? Take the podcast survey.

Introducing Carlat Total Access Subscriptions

Complete access to every article you search on the website.

Shop For Total Access

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    Treating Alcohol Use Disorder: A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto45285952.jpg
    Hospital Psychiatry

    Confused About Acute Confusional States? A Primer on Delirium

    Delirium is widespread among patients in ICUs and surgery units. In this podcast, we will review the workup and management of this common condition and give you tips to help...

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.